Trials / Terminated
TerminatedNCT00872300
PHA-739358 for the Treatment of Multiple Myeloma
An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHA-739358 | Weekly IV infusion for 3 consecutive weeks in a 4-week cycle |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-09-01
- Completion
- 2010-09-01
- First posted
- 2009-03-31
- Last updated
- 2014-05-28
Locations
4 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT00872300. Inclusion in this directory is not an endorsement.